Agenda
November 2023 | Virtual Meeting via WebEx
(Please note, the following times are approximate and all times are ET)
| November 3, 2023 | ||
| 1:30 pm - 2:00 pm | Join Meeting - Computer Check | |
| 2:00 pm - 2:05 pm | Welcome Piotr Grodzinski, Ph.D., Branch Chief, NSDB, CIP, DCTD, NCI |
|
| 2:05 pm - 2:30 pm | Introduction Carolina Salvador Morales, Ph.D., Program Director, NSDB, CIP, DCTD, NCI |
|
|
SESSION I (PART 1) : CRITERIA FOR SELECTING A CANCER INDICATION FOR SUCCESSFUL NANO-BASED INTERVENTIONS
MODERATOR: Carolina Salvador Morales, Ph.D., Program Director, NSDB, CIP, DCTD, NCI |
||
| 2:30 pm - 3:00 pm | How does the selection of cancer indication drive nanotherapeutics design? Gregory Lanza, MD., Ph.D., Washington University School of Medicine St Louis |
|
| 3:00 pm - 3:30 pm | What cancers are most suitable for nanomedicine treatments? Joelle Straehla, MD., Massachusetts Institute of Technology |
|
| 3:30 pm - 4:15 pm | What are the significant clinical and technical challenges associated with colorectal, pancreatic, and ovarian cancer nanotherapeutics? Colorectal cancer, Wenbin Lin, Ph.D., University of Chicago Pancreatic cancer, Andre E. Nel, M.D., Ph.D., University of California at Los Angeles Ovarian cancer, John Martignetti, M.D., Ph.D., Icahn School of Medicine at Mount Sinai |
|
| 4:15 pm - 4:45 pm | What are animal model challenges for the development and evaluation of cancer nanotherapeutics? Kinam Park, Ph.D., Purdue University Elias Sayour, MD., Ph.D., University of Florida |
|
| 4:45: pm - 5:15 pm | Q&A session Peter Ujhazy, Ph.D., Program Director, Translational Research Program, DCTD, NCI |
|
| November 8, 2023 | ||
|
SESSION I (PART 2): CRITERIA FOR SELECTING A CANCER INDICATION FOR SUCCESSFUL NANO-BASED INTERVENTIONS
MODERATOR: Natalia Mercer, Ph.D., Program Director, Division of Cancer Biology, NCI |
||
| 1:30 pm - 2:00 pm | Join Meeting - Computer Check | |
| 2:00 pm - 3:00 pm | Does tumor microenvironment (TME) influence different therapeutic strategies? Alexis Combes, Ph.D., University of California San Francisco Peter Nelson, M.D., Ph.D., Fred Hutchinson Cancer Center |
|
| 3:00 pm - 4:00 pm | What studies should be undertaken to further understand interactions between nanotherapeutics and the TME for different cancers? Andrew Wang, M.D., UT Soutwestern Medical Center Pan Chong-Xian, M.D., Ph.D., Brigham and Women's Hospital |
|
| 4:00 pm - 4:30 pm | What critical components of the TME are responsible for enhancing nanoparticle accumulation in the tumor site? Miles Miller, Ph.D., Massachusetts General Hospital |
|
| 4:30 pm - 5:00 pm | Q&A session Yali Fu, Ph.D., Program Director, DTP, DCTD, NCI |
|
| November 14, 2023 | ||
|
Session II. ADVANCING CLINICAL TRANSLATION OF NANOTHERAPEUTICS
Moderator: Michelle Bradbury, MD., Ph.D., Weill Cornell Medicine |
||
| 1:30 pm - 2:00 pm | Join Meeting - Computer Check | |
| 2:00 pm - 2:30 pm | What are current FDA requirements to assess safety and efficacy of nanotherapeutics? Wimolnut Manheng, Ph.D., DABT, US Food and Drug Administration |
|
| 2:30 pm - 3:00 pm | How new technologies (e.g., artificial intelligence and organ-on-a-chip systems) can aid in designing better nanotherapeutics? Chrysafis Andreou, Ph.D., University of Cyprus |
|
| 3:00 pm - 4:00 pm | How patient stratification combined with specific cancer indication selection can improve success of nanotherapeutic clinical trials? Twan Lammers, Ph.D., RWTH AACHEN University Rafael Torres, Ph.D., King's College London |
|
| 4:00 pm - 4:30 pm | How to promote and enhance interactions between clinicians and scientists to improve effectiveness and design of nanotherapeutics? Jung Soo Suk, Ph.D., Johns Hopkins University Wen Jiang, M.D., Ph.D., University of Texas MD Anderson Cancer Center |
|
| 4:30 pm - 5:00 pm | Q& A session Stephan T. Stern, Ph.D., D.A.B.T., Nanotechnology Characterization Lab |
|
| 5:00 pm - 5:15 pm | Closing Remarks Carolina Salvador Morales, Program Director, NSDB, CIP, DCTD, NCI |
|